聚醇在治疗性结肠炎的辅助剂中的有效性:随机对照试验的元分析
Qiuxiang Wang1, Liuying Li2, Shuhan Zhuang3
1Department of Traditional Chinese Medicine, Guangyuan Central Hospital, Sichuan Province, China.
Medicine
|May 26, 2025
概括
聚醇显著改善了性结肠炎患者的缓解和反应率. 这次元分析没有发现增加的不良影响,这表明多是一种安全有效的治疗选择.
科学领域:
- 胃肠病学 胃肠病学
- 临床营养学 临床营养学
- 药理学 药理学是指药理学的学科.
背景情况:
- 聚醇在性结肠炎 (UC) 管理中的治疗作用受到争议.
- 现有的关于UC中多的有效性和安全性的证据需要全面的合成.
研究的目的:
- 系统评估多补充剂治疗性结肠炎的疗效和安全性.
- 提供对聚醇对UC患者临床和内镜结果的影响的定量评估.
主要方法:
- 一个系统的审查和元分析,遵循PRISMA 2020指南.
- 在主要数据库 (PubMed,Embase,Web of Science,Cochrane) 进行全面的文献搜索.
- 随机效应模型用于计算赔率比率 (OR) 和95%置信区间 (CI).
主要成果:
- 分析了13项涉及742名参与者的试验,显示多的临床缓解和响应率显著更高.
- 与对照组相比,聚醇组的内镜缓解率也更高.
- 在多和对照组之间没有观察到不良事件发生率的统计学上显著差异.
结论:
- 多在诱导性结肠炎患者的临床缓解,临床反应和内镜缓解方面是有效的.
- 多补充剂在UC治疗中似乎是安全的,没有增加副作用的风险.
- 这些发现支持考虑多作为性结肠炎管理中的辅助疗法.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
248
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
248
Inflammatory Bowel Disease IV: Pharmacological Management
205
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
205
Drugs for Treatment of Diarrhea-Predominant IBS
317
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
317
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
433
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
433
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
611
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
611
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
212
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
212


